Cargando…

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma

Non-small cell lung cancer is a subtype of adenocarcinoma, which has previously shown positive responses to gefitinib. The aim of the current study was to determine a clinical profile of gefitinib-induced disease controls for patients with lung adenocarcinoma. Retrospective evaluation of the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	WANG, ZHUN, HAN, QIAN-BO, GU, JIA-LEI, YU, XIN-MIN, SUN, XIAO-JIANG, LIN, QING-REN, FANG, JUN, WANG, YUE-ZHEN, XU, YA-PING, MAO, WEI-MIN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246704/ https://www.ncbi.nlm.nih.gov/pubmed/25435970 http://dx.doi.org/10.3892/ol.2014.2664

Ejemplares similares

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
por: Ni, Xiao Ling, et al.
Publicado: (2017)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Identification of Key Genes and Pathways in Gefitinib-Resistant Lung Adenocarcinoma using Bioinformatics Analysis
por: Mao, Kailin, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
por: Li, Ya‐Qing, et al.
Publicado: (2017)

Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models
por: Yu, Ya-Ya, et al.
Publicado: (2021)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

Erratum to “Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models”
por: Yu, Ya-Ya, et al.
Publicado: (2022)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
por: Yao, Wenxiu, et al.
Publicado: (2020)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
por: Liu, Yu-Tao, et al.
Publicado: (2015)

The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features
por: Ochi, Mieko, et al.
Publicado: (2018)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Gene-carried hepatoma targeting complex induced high gene transfection efficiency with low toxicity and significant antitumor activity
por: Zhao, Qing-Qing, et al.
Publicado: (2012)

Hinokitiol Induces DNA Damage and Autophagy followed by Cell Cycle Arrest and Senescence in Gefitinib-Resistant Lung Adenocarcinoma Cells
por: Li, Lan-Hui, et al.
Publicado: (2014)

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients
por: Zou, Junyong, et al.
Publicado: (2022)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Severe stomatitis caused by osimertinib combined with gefitinib: A case report
por: Zhu, Ya‐ning, et al.
Publicado: (2022)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Expression and Significance of FXYD-3 Protein in Gastric Adenocarcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2010)

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Orbital metastasis secondary to pulmonary adenocarcinoma treated with gefitinib: a case report
por: Koma, Yasuko, et al.
Publicado: (2012)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
por: Maeda, Ai, et al.
Publicado: (2016)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
por: Wang, Yue-qin, et al.
Publicado: (2020)

PINCH Expression and Its Clinicopathological Significance in Gastric Adenocarcinoma
por: Zhu, Zhen-Long, et al.
Publicado: (2012)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\ASC\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib
por: Fang, Yue, et al.
Publicado: (2022)

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
por: Xu, Wei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_58lrlacngee7mvqn46rugm360e